archive_header_en_20251203154432269.png

icon_20251203182619268.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

<br>Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Optimization of PDE4 Inhibitors for Topical Application - Difamilast, A Novel Therapeutic Agent for Atopic Dermatitis -

Humans and other organisms use their five senses to recognize a variety of physical and chemical information from the external world for their survival and preservation. For tissue damage and harmful stimuli, however, the nociceptive system and its associated pain and itch sensations play an important role as a defense system. Our understanding of the molecular mechanisms for nociception has been greatly advanced by the discovery of TRPV1 channels (the Nobel Prize in Physiology or Medicine in 2021) and of other sensor molecules (e.g., receptors and ion channels, and enzymes). In addition, the recent discovery of a neural subset that selectively transmits itch signals has revealed itch-selective neural pathway. Contrary, under disease conditions (e.g., cancer, diabetes, and atopic dermatitis), these functions are pathologically altered, which in turn causes chronic pain and itch. The underlying mechanisms are poorly understood, but recent studies have proposed that chronic pain and itch are not simply a consequence of the continuity of these acute signals but rather involve a malfunction in the pain and itch networks of the nervous system. This symposium invites researchers who have been working at the forefront will show their latest, interesting findings that have uncovered new mechanisms for pain and itch and their chronicity, and based on their findings we will also discuss new concepts for drug discovery, and future challenges and prospects.

The Pharmaceutical Society of Japan

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

[ISS01-03]Optimization of PDE4 Inhibitors for Topical Application - Difamilast, A Novel Therapeutic Agent for Atopic Dermatitis -

Password required to view